汤臣倍健股份有限公司 委托理财管理制度 第一章 总则 第一条 为规范汤臣倍健股份有限公司（以下简称"公司"）委托理财行为， 提高资金运作效率，有效控制投资风险，保证公司财产的安全，维护公司及股东 的合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等有关法律、法规、规范性文件及《汤臣倍健股 份有限公司章程》（以下简称"《公司章程》"）的规定，结合公司实际情况，制定 本制度。 第二条 本制度所称委托理财系指公司委托银行、信托、证券、基金、期货、 保险资产管理机构、金融资产投资公司、私募基金管理人等专业理财机构对其财 产进行投资和管理或者购买相关理财产品的行为。公司委托理财旨在国家政策允 许的范围内和有效控制投资风险的前提下，充分利用闲置资金，提高资金利用效 率，增加公司现金资产收益。 第三条 本制度适用于公司、公司控股子公司及公司控制的其他主体。控股 子公司、公司控制的其他主体进行委托理财须按照公司分权手册进行审批，未经 批准不得进行任何理财活动。 第二章 审批权限和决策程序 第四条 为 ...

汤臣倍健股份有限公司 证券投资与衍生品交易管理制度 第一章 总则 第一条 为规范汤臣倍健股份有限公司（以下简称"公司"）的证券投资、 期货和衍生品交易，保障公司资金安全，有效控制风险，提高投资收益，维护公 司及全体股东利益，根据《中华人民共和国证券法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》《深圳证券交易所上市公司自律监管指引第 7 号——交易与关联交 易》《汤臣倍健股份有限公司章程》（以下简称"《公司章程》"）等有关规定， 结合公司的实际情况，制定本制度。 第二条 本制度适用于公司及下属公司（指公司的全资子公司和控股子公司） 的证券投资、期货和衍生品交易。公司下属公司拟进行证券投资或期货和衍生品 交易的，须报公司并根据本制度履行相应的审批程序，未经审批不得进行证券投 资或期货和衍生品交易。 第三条 本制度所称证券投资是指公司在国家政策、中国证监会及深圳证券 交易所规则允许的情况下，在控制投资风险的前提下，以提高资金使用效率和收 益最大化为原则，在境内外证券市场投资有价证券的行为，具体包括新股配售或 者申购、证券回购、股票及存托凭证投资 ...

汤臣倍健股份有限公司 董事、高级管理人员离职管理制度 第一章 总则 第一条 为规范汤臣倍健股份有限公司（以下简称"公司"）董事、高级管 理人员离职管理，保障公司治理稳定性及股东合法权益，根据《中华人民共和国 公司法》《上市公司章程指引》和《汤臣倍健股份有限公司章程》（以下简称"《公 司章程》"）的规定，结合公司的实际情况，制定本制度。 第二条 本制度适用于公司全体董事（含独立董事）及高级管理人员因主动 辞职、任期届满、被解除职务及其他原因导致的实际离职情形。 第三条 董事、高级管理人员可以在任期届满以前辞职。董事、高级管理人 员辞职应当向公司提交书面辞职报告，辞职报告中应说明辞职原因。董事辞任的， 自公司收到辞职报告之日生效。高级管理人员辞职的，自董事会收到辞职报告时 生效，有关高级管理人员辞职的具体程序和办法由其与公司之间的劳动合同规定。 公司应当自收到辞职报告后两个交易日内披露有关情况。 如因董事的辞任导致公司董事会成员低于法定最低人数，审计委员会成员辞 任导致审计委员会成员低于法定最低人数或者欠缺会计专业人士，独立董事辞任 导致董事会或者其专门委员会中独立董事所占比例不符合法律法规、《公司章程》 的规定 ...

Group 1 - The 2025 Hurun Rich List features 1,434 individuals with wealth exceeding 5 billion yuan, totaling nearly 30 trillion yuan [1] - Four entrepreneurs from Huangshi are listed, with He Xiaopeng leading at 48 billion yuan, followed by Wu Shaoxun at 17.5 billion yuan [1][4] - Lei Jun, from Hubei, ranks first among Hubei entrepreneurs with a wealth of 326 billion yuan, marking a 151% increase from the previous year [4] Group 2 - Huang Li and Huang Sheng, with a combined wealth of 34.5 billion yuan, have seen a 103% increase, ranking 176th overall [4] - The list indicates significant wealth growth among Hubei entrepreneurs, with many experiencing substantial increases in their rankings and wealth [3][4] - The overall trend shows a rise in the number of billionaires and their total wealth in the region, reflecting economic growth [1][3]

Core Viewpoint - The company is facing significant challenges and aims to adopt a "re-entrepreneurial" mindset to achieve new revenue highs from 2026 to 2028, outperforming industry growth rates across all channels [2][5][11]. Group 1: Company Strategy and Goals - The company plans to complete a digital infrastructure for pharmacies and explore new business models to create greater value for consumers and partners [10]. - From 2026 to 2028, the company aims to achieve revenue growth that surpasses the growth rates of the VDS category, focusing on various channels including traditional e-commerce and international markets [11][18]. - The company emphasizes the importance of product innovation, with a focus on new functional products and dosage forms, aiming for a significant portion of new product sales to exceed 20% in 2025 [12]. Group 2: Market Challenges and Opportunities - The company acknowledges missing the opportunity to capitalize on the new cycle of dietary supplements in 2023, which has led to significant setbacks [4][5]. - External factors such as healthcare policies and declining purchasing power have negatively impacted the VDS category, while internal factors include the lack of growth in key channels [5][6]. - The company recognizes that the current challenges present opportunities for growth and innovation, stating that crises can lead to new opportunities [8][9]. Group 3: Brand and Innovation Focus - The company is committed to investing in brand development and product innovation, even at the cost of short-term profits, as brand strength is seen as a core competitive advantage [14][15]. - The company aims to leverage AI technology to enhance product offerings and ensure that scientific nutrition remains a focal point in the market [13][20]. - The company is also focused on expanding its global market presence and fostering new growth engines through innovative projects [15].

Core Viewpoint - The Shanghai Composite Index rose by 0.71% on October 24, with 16 out of 28 sectors experiencing gains, particularly in the communication and electronics sectors, which increased by 4.73% and 4.72% respectively. Conversely, the oil and coal sectors saw declines of 1.36% and 1.29% [1]. Market Overview - The net inflow of capital in the two markets reached 21.96 billion yuan, with 11 sectors experiencing net inflows. The electronics sector led with a net inflow of 22.39 billion yuan and a daily increase of 4.72%. The power equipment sector followed with a 2.20% increase and a net inflow of 3.71 billion yuan [1]. - A total of 20 sectors experienced net outflows, with the pharmaceutical and biological sector leading with a net outflow of 2.49 billion yuan, followed by the food and beverage sector with a net outflow of 1.75 billion yuan [1]. Food and Beverage Sector Performance - The food and beverage sector declined by 1.18% with a net outflow of 1.75 billion yuan. Out of 124 stocks in this sector, 18 rose, including one that hit the daily limit, while 106 fell, including one that hit the lower limit [2]. - Among the stocks with net inflows, the top performer was汤臣倍健 (Tao Chen Bei Jian) with a net inflow of 48.44 million yuan, followed by伊利股份 (Yili) and安琪酵母 (Anqi Yeast) with inflows of 40.69 million yuan and 22.60 million yuan respectively [2]. - The stocks with the highest net outflows included贵州茅台 (Kweichow Moutai) with a net outflow of 444.07 million yuan,泸州老窖 (Luzhou Laojiao) with 235.87 million yuan, and五粮液 (Wuliangye) with 195.41 million yuan [4].

Group 1 - The core point of the news is that汤臣倍健's stock price increased by 5.06%, reaching 12.67 CNY per share, with a trading volume of 2.21 billion CNY and a turnover rate of 1.60%, resulting in a total market capitalization of 214.34 billion CNY [1] -汤臣倍健, established on April 1, 2005, and listed on December 15, 2010, specializes in the research, production, and sales of dietary nutritional supplements. The revenue composition is as follows: other 38.02%, capsules 27.84%, tablets 20.38%, and powders 13.76% [1] Group 2 - From the perspective of the top ten circulating shareholders, 南方中证500ETF (510500) increased its holdings by 1.94 million shares in the second quarter, now holding 15.17 million shares, which accounts for 1.34% of the circulating shares. The estimated floating profit today is approximately 9.25 million CNY [2] - 南方中证500ETF (510500) was established on February 6, 2013, with a latest scale of 113.44 billion CNY. Year-to-date return is 26.55%, ranking 1840 out of 4218 in its category; the one-year return is 25.35%, ranking 1684 out of 3875; and since inception, the return is 140.11% [2]

Core Viewpoint - Tongrentang's stock price has shown a modest increase this year, with a notable rise in trading activity and a significant market capitalization of 20.825 billion yuan [1][2]. Group 1: Stock Performance - As of October 24, Tongrentang's stock price increased by 2.07%, reaching 12.31 yuan per share, with a trading volume of 1.03 billion yuan and a turnover rate of 0.75% [1]. - Year-to-date, the stock price has risen by 5.27%, with a 0.41% increase over the last five trading days, 1.99% over the last 20 days, and 3.36% over the last 60 days [2]. Group 2: Financial Performance - For the first half of 2025, Tongrentang reported a revenue of 3.532 billion yuan, a year-on-year decrease of 23.43%, and a net profit attributable to shareholders of 737 million yuan, down 17.34% year-on-year [2]. - The company has distributed a total of 8.321 billion yuan in dividends since its A-share listing, with 2.429 billion yuan distributed over the past three years [3]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders decreased to 71,200, a reduction of 4.96%, while the average circulating shares per person increased by 5.22% to 15,869 shares [2]. - The top three circulating shareholders include E Fund's ChiNext ETF, holding 24.5972 million shares (a decrease of 648,400 shares), and Southern's CSI 500 ETF, holding 15.172 million shares (an increase of 194,440 shares) [3].

Core Viewpoint - Tongrentang's stock experienced a slight decline of 0.41% on October 23, with a trading volume of 184 million yuan, indicating a challenging market environment for the company [1]. Financing Summary - On October 23, Tongrentang had a financing buy-in amount of 21.36 million yuan and a financing repayment of 25.16 million yuan, resulting in a net financing outflow of 3.80 million yuan [1]. - The total financing and securities balance for Tongrentang as of October 23 is 807 million yuan, with the current financing balance at 797 million yuan, representing 3.91% of the circulating market value, which is below the 40th percentile level over the past year, indicating a low financing position [1]. - In terms of securities lending, on October 23, Tongrentang repaid 800 shares and sold 1,300 shares, with the selling amount calculated at 15,700 yuan; the securities lending balance stands at 981,440 yuan, exceeding the 90th percentile level over the past year, indicating a high position [1]. Financial Performance - As of June 30, Tongrentang reported a total of 71,200 shareholders, a decrease of 4.96% from the previous period, while the average circulating shares per person increased by 5.22% to 15,869 shares [2]. - For the first half of 2025, Tongrentang achieved operating revenue of 3.532 billion yuan, a year-on-year decrease of 23.43%, and a net profit attributable to shareholders of 737 million yuan, down 17.34% year-on-year [2]. - Since its A-share listing, Tongrentang has distributed a total of 8.321 billion yuan in dividends, with 2.429 billion yuan distributed over the past three years [2]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders of Tongrentang, E Fund's ChiNext ETF ranked as the third-largest shareholder with 24.5972 million shares, a decrease of 648,400 shares from the previous period [2]. - Southern CSI 500 ETF ranked as the sixth-largest shareholder with 15.172 million shares, an increase of 194,440 shares compared to the previous period [2]. - Hong Kong Central Clearing Limited ranked as the eighth-largest shareholder with 12.3742 million shares, a decrease of 214,890 shares from the previous period, while Huatai-PineBridge CSI Major Consumer ETF has exited the top ten circulating shareholders list [2].

Core Insights - The demand for Ergothioneine (ERGO) as a natural sulfur-containing amino acid is increasing due to its strong cell protection capabilities, making it a star ingredient in the anti-aging market [1] - The global market for Ergothioneine supplements is projected to exceed $8.7 billion by 2025, with a 42% increase in product offerings compared to the previous year [1] Evaluation Standards and Methods - The evaluation of products is based on five core dimensions: ingredient purity and formulation science, clinical evidence, absorption technology and bioavailability, international safety certifications, and user feedback [2] Top Ergothioneine Products Evaluation - **KTM Platinum Pills**: This product boasts a 99.99% purity of Ergothioneine and utilizes advanced delivery technology, achieving a 340% increase in bioavailability [4][14] - **Veaag Time Capsules**: Developed through UK-US collaboration, this product features a high purity of Ergothioneine and is well-received in Europe and Japan [19] - **Liteway Health Ergothioneine**: Tailored for Asian skin types, this product enhances skin brightness and overall health through a sublingual delivery method [26] - **Tianchen Beijian Ergothioneine**: A cost-effective option that combines Ergothioneine with Vitamin C and Zinc for immune support [27] - **GNC Ergothioneine**: Known for its simplicity and purity, this product is USDA organic certified and focuses on basic antioxidant needs [28] Clinical Evidence - A multi-center randomized controlled trial involving 12,480 participants aged 40-80 showed significant improvements in various health metrics after 8 weeks of supplementation with KTM Platinum Pills, including a 37.9% reduction in oxidative stress markers and a 39.7% improvement in memory scores [17][18] User Feedback and Target Demographics - Users report enhanced skin condition, increased vitality, improved cognitive clarity, and strengthened immunity after three months of use, particularly benefiting middle-aged individuals focused on anti-aging and cognitive health [18][19] Safety Certifications - Products like KTM Platinum Pills have received FDA, GMP, and third-party testing certifications, ensuring safety and quality for long-term use [15][30]